首页> Circulation> Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.

Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.

导出 OA

翻译打印收藏纠错

第一作者： Barry A,Borlaug

第一单位： Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).

作者： Barry A,Borlaug ^[1] ; John,Blair ^[2] ; Martin W,Bergmann ^[3] ; Heiko,Bugger ^[4] ; Dan,Burkhoff ^[5] ; Leonhard,Bruch ^[6] ; David S,Celermajer ^[7] ; Brian,Claggett ^[8] ; John G F,Cleland ^[9] ; Donald E,Cutlip ^[10] ; Ira,Dauber ^[11] ; Jean-Christophe,Eicher ^[12] ; Qi,Gao ^[10] ; Thomas M,Gorter ^[13] ; Finn,Gustafsson ^[14] ; Chris,Hayward ^[15] ; Jan,van der Heyden ^[16] ; Gerd,Hasenfuß ^[17] ; Scott L,Hummel ^[18] ; David M,Kaye ^[19] ; Jan,Komtebedde ^[20] ; Joseph M,Massaro ^[21] ; Jeremy A,Mazurek ^[22] ; Scott,McKenzie ^[23] ; Shamir R,Mehta ^[24] ; Mark C,Petrie ^[25] ; Marco C,Post ^[26] ; Ajith,Nair ^[27] ; Andreas,Rieth ^[28] ; Frank E,Silvestry ^[22] ; Scott D,Solomon ^[8] ; Jean-Noël,Trochu ^[29] ; Dirk J,Van Veldhuisen ^[13] ; Ralf,Westenfeld ^[30] ; Martin B,Leon ^[5] ; Sanjiv J,Shah ^[31] ; REDUCE LAP-HF-II Investigators

作者单位： Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.). ^[1] University of Chicago (J.B.). ^[2] Cardiologicum Hamburg, Germany (M.W.B.). ^[3] Medical University of Graz, Austria (H.B.). ^[4] Cardiovascular Research Foundation, New York, NY (D.B., M.B.L.). ^[5] BG Klinikum Unfallkrankenhaus, Berlin, Germany (L.B.). ^[6] Royal Prince Alfred Hospital, The University of Sydney, Australia (D.S.C.). ^[7] Brigham and Women's Hospital, Boston, MA (B.C., S.D.S.). ^[8] Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit, Institute of Health and Wellbeing, United Kingdom (J.G.F.C.).;National Heart & Lung Institute, Imperial College London, United Kingdom (J.G.F.C.). ^[9] Baim Clinical Research Institute, Boston, MA (D.E.C., Q.G.). ^[10] South Denver Cardiology Associates/Centura Health, CO (I.D.). ^[11] CHU de Dijon-Hôpital Bocage Central, Dijon, France (J.-C.E.). ^[12] University of Groningen, University Medical Center Groningen, The Netherlands (T.M.G., D.J.V.V.). ^[13] Rigshospitalet, University of Copenhagen, Denmark (F.G.). ^[14] St Vincents Hospital Sydney, Australia (C.H.). ^[15] AZ Sint-Jan Brugge-Oostende, Bruges, Belgium (J.v.d.H.). ^[16] Heart Center, University Medical Center, Göttingen, Germany (G.H.). ^[17] University of Michigan, Ann Harbor (S.L.H.).;VA Ann Arbor Health System, MI (S.L.H.). ^[18] Alfred Hospital, Melbourne, Australia (D.M.K.). ^[19] Corvia Medical Inc, Tewksbury, MA (J.K.). ^[20] Boston University School of Public Health, MA (J.M.M.). ^[21] Hospital of the University of Pennsylvania, Philadelphia (J.A.M., F.E.S.). ^[22] Prince Charles Hospital, Brisbane, Australia (S.M.). ^[23] McMaster University and Hamilton Health Sciences, Hamilton, Canada (S.R.M.). ^[24] University of Glasgow, Scotland (M.C. Petrie). ^[25] Departments of Cardiology, St Antonius Hospital Nieuwegein and University Medical Center Utrecht, the Netherlands (M.C. Post). ^[26] Baylor College of Medicine, Houston, TX (A.N.). ^[27] Kerckhoff Heart and Thoraxcenter, Bad Nauheim, Germany (A.R.). ^[28] l'Institut du Thorax, CHU Nantes, Nantes Université, CNRS, INSERM, Nantes, France (J.-N.T.). ^[29] Division of Cardiology, Pulmonology, and Vascular Medicine Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany (R.W.). ^[30] Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.). ^[31]

关键词 clinical trial heart failure hypertension, pulmonary lung diseases therapeutics vascular diseases